This prospective observational study aimed to examine the pharmacokinetics of ropivacaine in patients with chronic kidney disease after sciatic nerve block. Sciatic nerve block for foot and ankle surgery will be performed using ropivacaine under ultrasound-guidance, and arterial blood test will be taken for total plasma ropivacaine concentration at 2.5, 5, 15, 30, 60 minutes and 2, 6, 24 hours after sciatic nerve block.
Study Type
OBSERVATIONAL
Enrollment
5
Sciatic nerve block will be performed using ropivacaine (2.5mg/kg) under ultrasound-guidance with nerve stimulator.
Seoul National University Hospital
Seoul, South Korea
Plasma concentration of unbound ropivacaine
whether the unbound plasma concentration of ropivacaine was maintained under 0.56 mcg/ml that was determined as toxic level in a previous study.
Time frame: 2.5, 5, 15, 30, 60 minutes and 2, 6, 24 hours after sciatic nerve block
Plasma concentration of 3-OH-ropivacaine
metabolite of ropivacaine
Time frame: 2.5, 5, 15, 30, 60 minutes and 2, 6, 24 hours after sciatic nerve block
Plasma concentration of pipecoloxylidide
metabolite of ropivacaine
Time frame: 2.5, 5, 15, 30, 60 minutes and 2, 6, 24 hours after sciatic nerve block
Postoperative pain score
11-point numeric rating scale ranging from '0' representing one extreme (e.g. "extremely dissatisfied") to '10' representing the other extreme (e.g. "extremely satisfied")
Time frame: 2, 6, 24 hours after sciatic nerve block
Local anesthetic systemic toxicity
numbness of the tongue, twitching, convulsion, dysarrhythmia, coma
Time frame: 2, 6, 24 hours after sciatic nerve block
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.